|
1
|
Zhang Y, Xu W, Li H, et al: Therapeutic
effects of total alkaloids of Tripterygium wilfordii Hook f. on
collagen-induced arthritis in rats. J Ethnopharmacol. 145:699–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vingsbo-Lundberg C, Nordquist N, Olofsson
P, et al: Genetic control of arthritis onset, severity and
chronicity in a model for rheumatoid arthritis in rats. Nat Genet.
20:401–404. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choy EH and Panayi GS: Cytokine pathways
and joint inflammation in rheumatoid arthritis. N Engl J Med.
344:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee Dm and Weinblatt MB: Rheumatoid
arthritis. Lancet. 15:903–911. 2001.
|
|
5
|
Schall A and Reiser O: Synthesis of
biologically active guaianolides with a trans-annulated lactone
moiety. Eur J Org Chem. 2008:2353–2364. 2008. View Article : Google Scholar
|
|
6
|
Ma WW, Shi QQ, Ding YH, et al: Synthesis
of micheliolide derivatives and their activities against AML
progenitor cells. Molecules. 18:5980–5992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhai JD, Li D, Long J, et al: Biomimetic
semisynthesis of arglabin from parthenolide. J Org Chem.
77:7103–7107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghantous A, Sinjab A, Herceg Z and
Darwiche N: Parthenolide: from plant shoots to cancer roots. Drug
Discov Today. 18:894–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Q, Lu Y, Ding Y, et al: Guaianolide
sesquiterpene lactones, a source to discover agents that
selectively inhibit acute myelogenous leukemia stem and progenitor
cells. J Med Chem. 55:8757–8769. 2012.
|
|
10
|
Sokka T and Pincus T: Contemporary disease
modifying antirheumatic drugs (DMARD) in patients with recent onset
rheumatoid arthritis in a US private practice:methotrexate as the
anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol.
29:2521–2524. 2002.PubMed/NCBI
|
|
11
|
Swierkot J and Szechiński J: Methotrexate
in rheumatoid arthritis. Pharmacol Rep. 58:473–492. 2006.
|
|
12
|
Cronstein BN: Low-dose methotrexate: a
mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev.
57:163–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pincus T, Yazici Y, Sokka T, et al:
Methotrexate as the “anchor drug” for the treatment of early
rheumatoid arthritis. Clin Exp Rheumatol. 21:S179–S185. 2003.
|
|
14
|
Van der, Heijden JW, Dijkmans BA, et al:
Drug Insight: resistance to methotrexate and other
disease-modifying antirheumatic drugs--from bench to bedside. Nat
Clin Pract Rheumatol. 3:26–34. 2007.PubMed/NCBI
|
|
15
|
Brand DD, Latham KA and Rosloniec EF:
Collagen-induced arthritis. Nat Protoc. 2:1269–1275. 2007.
View Article : Google Scholar
|
|
16
|
Suszko A and Obminska-Mrukowicz B:
Influence of polysaccharide fractions isolated from Caitha
palustris L. on the cellular immune response in collagen-induced
arthritis (CIA) in mice. A comparison with methotrexate. J
Ethnopharmacol. 145:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cuzzocrea S, Ayroldi E, Di Paola R, et al:
Role of glucocorticoid-induced TNF receptor family gene (GITR) in
collagen-induced arthritis. FASEB J. 19:1253–1265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xinqiang S, Fei L, Nan L, Yuan L, et al:
Therapeutic efficacy of experimental rheumatoid arthritis with
low-dose methotrexate by increasing partially CD4+CD25+Treg cells
and inducing Th1 to Th2 shift in both cells and cytokines. Biomed
Pharmacother. 64:463–471. 2010. View Article : Google Scholar
|
|
19
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wildbaum G, Nahir MA and Karin N:
Beneficial autoimmunity to proinflammatory mediators restrains the
consequences of self-destructive immunity. Immunity. 19:679–688.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sinha AA, Lopez MT and McDevitt HO:
Autoimmune diseases: the failure of self tolerance. Science.
248:1380–1388. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou J, Xiao C, Zhao L, et al: The effect
of triptolide on CD4+ and CD8+ cells in Peyer’s patch of SD rats
with collagen induced arthritis. Int Immunopharmacol. 6:198–203.
2006.
|
|
23
|
Ma N, Xing C, Xiao H, et al: C5a regulates
IL-12 (+) DC migration to induce pathogenic Th1 and Th17 cells in
sepsis. PLoS One. 8:e697792013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laudes IJ, Chu JC, Huber-Lang M, et al:
Expression and function of C5a receptor in mouse microvascular
endothelial cells. J Immunol. 169:5962–5970. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ries C: Cytokine functions of TIMP-1. Cell
Mol Life Sci. 71:659–672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Djafarzadeh R, Mojaat A, Vicente AB, et
al: Exogenously added GPI-anchored tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1) displays enhanced and novel biological
activities. Biol Chem. 385:655–663. 2004. View Article : Google Scholar
|
|
27
|
Souza PP and Lerner UH: The role of
cytokines in inflammatory bone loss. Immunol Invest. 42:555–622.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fei X, Hongxiang Z, Qi C and Daozhen C:
Maternal plasma levels of endothelial dysfunction mediators
including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia. Adv Clin Exp
Med. 21:573–579. 2012.PubMed/NCBI
|
